CommercialMay 30, 2018
Empire expands Specialty Pharmacy Clinical Site of Care (Level of Care) drug list
Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem.
Effective for dates of service on and after September 1, 2018, the following specialty pharmacy codes from new or current medical policies or clinical UM guidelines will be included in our existing specialty pharmacy level of care review process.
Empire’s level of care prior authorization clinical review of these specialty pharmacy drugs will be managed by AIM Specialty Health® (AIM), a separate company.
View the Clinical Site of Care (Level of Care) drug list and Clinical Site of Care (Level of Care) priro authorization clinical review FAQs for more information.
Medical Policy or Clinical Guideline |
Drug |
Code |
CG-DRUG-09 |
CuvitruTM |
J1555 |
DRUG.00081 |
Exondys 51TM |
J1428 |
CG-DRUG-78 |
Fibryga® |
J7178 |
DRUG.00093 |
KanumaTM |
J2840 |
CG-DRUG-44 |
Krystexxa® |
J2507 |
CG-DRUG-05 |
Mircera® |
J0888 |
DRUG.00095 |
OcrevusTM |
J2350 |
DRUG.00027 |
Prialt® |
J2278 |
CG-DRUG-78 |
Rebinyn® |
J7195 |
CG-DRUG-69 |
Stelara® |
J3358 |
CG-DRUG-61 |
Supprelin LA® |
J9226 |
CG-DRUG-16 |
Zarxio® |
Q5101 |
PUBLICATIONS: June 2018 Empire Provider Newsletter
To view this article online:
Or scan this QR code with your phone